donepezil has been researched along with Aging in 57 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The comparative effects of a newly described specific alpha7 nAChR partial agonist, S 24795, and a cholinesterase inhibitor, donepezil, currently used as a symptomatic Alzheimer's disease treatment were studied in two mouse models of aging-related memory deficits." | 7.74 | Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. ( Desmedt, A; Marighetto, A; Morain, P; Philippin, JN; Trocmé-Thibierge, C; Valerio, S, 2008) |
| "Ferulic acid (FA) acts as a powerful antioxidant against various age-related diseases." | 5.43 | Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model. ( Gao, J; Gao, W; Huo, L; Qu, Z; Yang, H; Zhang, J, 2016) |
| "The aim of the present study was to observe the effects of the concurrent administration of thyroxine (T4) and an acetylcholinesterase (AChE) inhibitor, donepezil (DON), on the hypothyroidism‑induced ultrastructural changes of the prefrontal cortex (PFC) in adult rats." | 3.85 | Concurrent administration of thyroxine and donepezil induces plastic changes in the prefrontal cortex of adult hypothyroid rats. ( Cai, Y; Jia, X; Wang, F; Wu, B; Wu, Z; Zha, X; Zhu, D, 2017) |
| "The comparative effects of a newly described specific alpha7 nAChR partial agonist, S 24795, and a cholinesterase inhibitor, donepezil, currently used as a symptomatic Alzheimer's disease treatment were studied in two mouse models of aging-related memory deficits." | 3.74 | Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. ( Desmedt, A; Marighetto, A; Morain, P; Philippin, JN; Trocmé-Thibierge, C; Valerio, S, 2008) |
| " From a review of the literature, the optimal technique employs quantitative 15O-water PET imaging determinations of cerebral blood flow (CBF) and acetazolamide (ACZ) (1 g iv with measurements at 10- to 20-min post-administration) as the vasodilating agent." | 3.72 | Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging. ( Boles Ponto, LL; Hichwa, RD; Leonard Watkins, G; Schultz, SK, 2004) |
| "The changes in extracellular acetylcholine levels were investigated by microdialysis in the cortex and hippocampus of aging rats after administration of metrifonate (80 mg/kg), rivastigmine (0." | 3.71 | Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. ( Bellucci, A; Casamenti, F; Costagli, C; Pepeu, G; Scali, C; Schmidt, B, 2002) |
| "Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy." | 3.01 | From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. ( Bennett, KA; Bradley, SJ; Broad, LM; Brown, AJH; Brown, GA; Brown, J; Browning, M; Bundgaard, C; Cansfield, JE; Christopoulos, A; Congreve, MS; Cooke, RM; Cross, DM; Dawson, GR; de Graaf, C; Deakin, JFW; Dias, JM; Dwomoh, L; Errey, JC; Goonawardena, AV; Hudson, BD; Hurrell, E; Jazayeri, A; Langmead, CJ; Liptrot, J; Marshall, FH; Mattedi, G; Molloy, C; Morairty, SR; Nathan, PJ; Okrasa, K; Osborne, G; Patel, JC; Perini, F; Phillips, K; Pickworth, M; Robertson, N; Rucktooa, P; Sexton, PM; Shahabi, S; Smith, RT; Tasker, T; Tehan, BG; Teobald, B; Tobin, AB; Vinson, M; Warneck, J; Weir, M, 2021) |
| "The donepezil group was more likely than the placebo group to experience recurrent major depression (35% [95% confidence interval {CI}, 24%-46%] vs 19% [95% CI, 9%-29%], respectively; log-rank χ² = 3." | 2.76 | Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. ( Anderson, S; Begley, A; Bensasi, S; Butters, MA; DeKosky, ST; Dew, MA; Gildengers, A; Holm, M; Houck, PR; Kamboh, MI; Karp, JF; Kaufer, DI; Lenze, EJ; Lopez, O; Mazumdar, S; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Rogers, JC; Stack, J; Szanto, K; Whyte, EM, 2011) |
| "Rapid eye movement sleep deprivation was achieved by REM sleep awakenings and compared with non-REM sleep awakenings." | 2.73 | The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication. ( Danker-Hopfe, H; Heuser, I; Hornung, OP; Regen, F; Schredl, M, 2007) |
| "A study was performed on patients with Alzheimer's disease (AD) in order to evaluate the efficacy of a combined treatment (donepezil plus cognitive training) in both cognitive processes and affective states." | 2.71 | Effects of cholinergic drugs and cognitive training on dementia. ( Campo, P; López Ibor, JJ; López Ibor, MI; Maestú, F; Ortiz, T; Requena, C, 2004) |
| "Donepezil treatment group: basal GH levels taken at 08:30 a." | 2.71 | The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease. ( Geyer, G; Huber, ER; Knechtelsdorfer, M; Mayerhofer, L; Mersich, N; Obermayr, RP; Tragl, KH, 2005) |
| " The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103." | 2.67 | Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ( Hasegawa, J; Kamakura, H; Mihara, M; Morishita, N; Ohnishi, A; Tanaka, T; Tomono, Y; Yamazaki, K, 1993) |
| " Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles." | 2.49 | Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. ( Eap, CB; Noetzli, M, 2013) |
| "Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes." | 2.49 | Atypical aging in Down syndrome. ( Zigman, WB, 2013) |
| " Improvement in behavioural symptoms also occurs, but without a dose-response relationship." | 2.41 | Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. ( Jann, MW; Shirley, KL; Small, GW, 2002) |
| "Treatment approaches to memory loss typically use Alzheimer's dementia as the template, and are discussed in this report." | 2.41 | Approaches to memory loss in neuropsychiatric disorders. ( Devi, G; Silver, J, 2000) |
| "Alzheimer's disease is the most common dementing illness affecting over 4 million Americans." | 2.40 | Providing dental care for patients diagnosed with Alzheimer's disease. ( Henry, RG; Wekstein, DR, 1997) |
| "Since aging and inflammation affect cognition and are risk factors for AD, these aspects were also evaluated." | 1.48 | The location discrimination reversal task in mice is sensitive to deficits in performance caused by aging, pharmacological and other challenges. ( Graf, R; Hughes, ZA; Longo, JL, 2018) |
| "Rolipram treatment significantly attenuated STZ induced and age related memory deficits, biochemical and histopathological alterations." | 1.46 | Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type. ( Kumar, A; Singh, N, 2017) |
| "Ferulic acid (FA) acts as a powerful antioxidant against various age-related diseases." | 1.43 | Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model. ( Gao, J; Gao, W; Huo, L; Qu, Z; Yang, H; Zhang, J, 2016) |
| "Memantine is a low-affinity voltage-dependent noncompetitive antagonist at glutamatergic NMDA receptors." | 1.42 | Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil. ( Akishita, M; Ogawa, S; Ota, H; Ouchi, Y, 2015) |
| " Intravenous and oral 6-h blood sampling profiles in old (30 months old) and young (7 months old) rats revealed pharmacokinetic changes similar to those in humans with an approximately 40% increase in C(max) of galantamine and prolonged t(1/2) (1." | 1.37 | Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. ( Aw, CC; Browne, ER; Chen, CP; Goh, CW; Lee, JH, 2011) |
| "Donepezil (1 mg/kg, vo) was administrated every day for 60 days to rats aged 10 and 18 months." | 1.36 | Enhanced dendritic spine number of neurons of the prefrontal cortex, hippocampus, and nucleus accumbens in old rats after chronic donepezil administration. ( Alcantara-Gonzalez, F; Camacho-Abrego, I; Flores, G; Juarez, I; Martinez-Tellez, I; Masliah, E; Mena, R; Solis, O, 2010) |
| "Older age, longer time between Alzheimer's disease diagnosis and first ChEI dispensing, lower dose of ChEI at treatment initiation and the presence of baseline depression and neuropsychiatric symptoms were associated with a significantly increased likelihood of antipsychotic drug use." | 1.36 | Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study. ( Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F, 2010) |
| " These results demonstrate that the PET imaging technique with specific labeled compounds in combination with microdialysis and a behavioral cognition task could be a useful method to clarify the mechanism of drugs in the living brains of experimental animals." | 1.32 | Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. ( Fukumoto, D; Kakiuchi, T; Nishiyama, S; Ohba, H; Sato, K; Tsukada, H, 2004) |
| "Donepezil treatment improved average task accuracy, but intersubject variability prohibited statistical significance." | 1.32 | Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys. ( Buccafusco, JJ; Terry, AV, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (5.26) | 18.2507 |
| 2000's | 22 (38.60) | 29.6817 |
| 2010's | 30 (52.63) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, AJH | 1 |
| Bradley, SJ | 1 |
| Marshall, FH | 1 |
| Brown, GA | 1 |
| Bennett, KA | 1 |
| Brown, J | 1 |
| Cansfield, JE | 1 |
| Cross, DM | 1 |
| de Graaf, C | 1 |
| Hudson, BD | 1 |
| Dwomoh, L | 1 |
| Dias, JM | 1 |
| Errey, JC | 1 |
| Hurrell, E | 1 |
| Liptrot, J | 1 |
| Mattedi, G | 1 |
| Molloy, C | 1 |
| Nathan, PJ | 1 |
| Okrasa, K | 1 |
| Osborne, G | 1 |
| Patel, JC | 1 |
| Pickworth, M | 1 |
| Robertson, N | 1 |
| Shahabi, S | 1 |
| Bundgaard, C | 1 |
| Phillips, K | 1 |
| Broad, LM | 1 |
| Goonawardena, AV | 1 |
| Morairty, SR | 1 |
| Browning, M | 1 |
| Perini, F | 1 |
| Dawson, GR | 1 |
| Deakin, JFW | 1 |
| Smith, RT | 1 |
| Sexton, PM | 1 |
| Warneck, J | 1 |
| Vinson, M | 1 |
| Tasker, T | 1 |
| Tehan, BG | 1 |
| Teobald, B | 1 |
| Christopoulos, A | 1 |
| Langmead, CJ | 1 |
| Jazayeri, A | 1 |
| Cooke, RM | 1 |
| Rucktooa, P | 1 |
| Congreve, MS | 1 |
| Weir, M | 1 |
| Tobin, AB | 1 |
| Guyot, AC | 1 |
| Leuxe, C | 1 |
| Disdier, C | 1 |
| Oumata, N | 1 |
| Costa, N | 1 |
| Roux, GL | 1 |
| Varela, PF | 1 |
| Duchon, A | 1 |
| Charbonnier, JB | 1 |
| Herault, Y | 1 |
| Pavoni, S | 1 |
| Galons, H | 1 |
| Andriambeloson, E | 1 |
| Wagner, S | 1 |
| Meijer, L | 1 |
| Lund, AK | 1 |
| Mabondzo, A | 1 |
| Wang, F | 1 |
| Wu, Z | 1 |
| Zha, X | 1 |
| Cai, Y | 1 |
| Wu, B | 1 |
| Jia, X | 1 |
| Zhu, D | 1 |
| Rahman, A | 1 |
| Lamberty, Y | 1 |
| Schenker, E | 1 |
| Cella, M | 1 |
| Languille, S | 1 |
| Bordet, R | 1 |
| Richardson, J | 1 |
| Pifferi, F | 1 |
| Aujard, F | 1 |
| Mulholland, PJ | 1 |
| Teppen, TL | 1 |
| Miller, KM | 1 |
| Sexton, HG | 1 |
| Pandey, SC | 1 |
| Swartzwelder, HS | 1 |
| Graf, R | 1 |
| Longo, JL | 1 |
| Hughes, ZA | 1 |
| Kumar, A | 2 |
| Singh, N | 2 |
| Noetzli, M | 1 |
| Eap, CB | 1 |
| Zigman, WB | 1 |
| Hashimoto, T | 1 |
| Hatayama, Y | 1 |
| Nakamichi, K | 1 |
| Yoshida, N | 1 |
| Mohamed, LA | 1 |
| Qosa, H | 1 |
| Kaddoumi, A | 1 |
| Puri, V | 1 |
| Wang, X | 1 |
| Vardigan, JD | 1 |
| Kuduk, SD | 1 |
| Uslaner, JM | 1 |
| Jiang, Y | 1 |
| Liu, Y | 2 |
| Zhu, C | 1 |
| Ma, X | 1 |
| Ma, L | 1 |
| Zhou, L | 1 |
| Huang, Q | 1 |
| Cen, L | 1 |
| Pi, R | 1 |
| Chen, X | 1 |
| Ota, H | 1 |
| Ogawa, S | 1 |
| Ouchi, Y | 1 |
| Akishita, M | 1 |
| Stein, C | 1 |
| Hopfeld, J | 1 |
| Lau, H | 1 |
| Klein, J | 1 |
| Johnson, SA | 1 |
| Sacks, PK | 1 |
| Turner, SM | 1 |
| Gaynor, LS | 1 |
| Ormerod, BK | 1 |
| Maurer, AP | 1 |
| Bizon, JL | 1 |
| Burke, SN | 1 |
| Yang, H | 1 |
| Qu, Z | 1 |
| Zhang, J | 1 |
| Huo, L | 1 |
| Gao, J | 1 |
| Gao, W | 1 |
| Mellios, G | 1 |
| Callahan, PM | 1 |
| Bertrand, D | 1 |
| Bertrand, S | 1 |
| Plagenhoef, MR | 1 |
| Terry, AV | 5 |
| Benetti, F | 1 |
| Mello, PB | 1 |
| Bonini, JS | 1 |
| Monteiro, S | 1 |
| Cammarota, M | 1 |
| Izquierdo, I | 1 |
| Gibbs, RB | 1 |
| Mauk, R | 1 |
| Nelson, D | 1 |
| Johnson, DA | 1 |
| Itou, Y | 1 |
| Nochi, R | 1 |
| Kuribayashi, H | 1 |
| Saito, Y | 1 |
| Hisatsune, T | 1 |
| Alcantara-Gonzalez, F | 2 |
| Juarez, I | 2 |
| Solis, O | 1 |
| Martinez-Tellez, I | 1 |
| Camacho-Abrego, I | 1 |
| Masliah, E | 1 |
| Mena, R | 1 |
| Flores, G | 2 |
| Scharre, DW | 1 |
| Vekeman, F | 1 |
| Lefebvre, P | 1 |
| Mody-Patel, N | 1 |
| Kahler, KH | 1 |
| Duh, MS | 1 |
| Goh, CW | 1 |
| Aw, CC | 1 |
| Lee, JH | 1 |
| Chen, CP | 1 |
| Browne, ER | 1 |
| Reynolds, CF | 1 |
| Butters, MA | 1 |
| Lopez, O | 1 |
| Pollock, BG | 1 |
| Dew, MA | 1 |
| Mulsant, BH | 1 |
| Lenze, EJ | 1 |
| Holm, M | 1 |
| Rogers, JC | 1 |
| Mazumdar, S | 1 |
| Houck, PR | 1 |
| Begley, A | 1 |
| Anderson, S | 1 |
| Karp, JF | 1 |
| Miller, MD | 1 |
| Whyte, EM | 1 |
| Stack, J | 1 |
| Gildengers, A | 1 |
| Szanto, K | 1 |
| Bensasi, S | 1 |
| Kaufer, DI | 1 |
| Kamboh, MI | 1 |
| DeKosky, ST | 1 |
| Tripathi, S | 1 |
| Mahdi, AA | 1 |
| Hasan, M | 1 |
| Mitra, K | 1 |
| Mahdi, F | 1 |
| Araujo, JA | 1 |
| Greig, NH | 1 |
| Ingram, DK | 1 |
| Sandin, J | 1 |
| de Rivera, C | 1 |
| Milgram, NW | 1 |
| Stefanacci, RG | 1 |
| Whitney, KN | 1 |
| Wenger, GR | 1 |
| Aisa, HA | 1 |
| Ji, C | 1 |
| Yang, N | 1 |
| Zhu, H | 1 |
| Zuo, P | 1 |
| Mendoza-Perez, CR | 1 |
| Zaragoza, N | 1 |
| Arroyo-García, LE | 1 |
| Gamboa, C | 1 |
| De La Cruz, F | 1 |
| Zamudio, S | 1 |
| Garcia-Dolores, F | 1 |
| Priyanka, HP | 1 |
| Singh, RV | 1 |
| Mishra, M | 1 |
| ThyagaRajan, S | 1 |
| Scali, C | 1 |
| Casamenti, F | 1 |
| Bellucci, A | 1 |
| Costagli, C | 1 |
| Schmidt, B | 1 |
| Pepeu, G | 1 |
| Tokita, K | 1 |
| Yamazaki, S | 1 |
| Yamazaki, M | 1 |
| Matsuoka, N | 2 |
| Mutoh, S | 1 |
| Jann, MW | 1 |
| Shirley, KL | 1 |
| Small, GW | 1 |
| Moriguchi, A | 1 |
| Nakano, K | 1 |
| Yamaguchi, I | 1 |
| Sano, K | 1 |
| Noda, K | 1 |
| Hashimoto, M | 1 |
| Ohara, K | 1 |
| Goto, T | 1 |
| Buccafusco, JJ | 3 |
| Jackson, WJ | 1 |
| Stone, JD | 1 |
| Ihl, R | 1 |
| Boles Ponto, LL | 1 |
| Schultz, SK | 1 |
| Leonard Watkins, G | 1 |
| Hichwa, RD | 1 |
| Tsukada, H | 1 |
| Nishiyama, S | 1 |
| Fukumoto, D | 1 |
| Ohba, H | 1 |
| Sato, K | 1 |
| Kakiuchi, T | 1 |
| Requena, C | 1 |
| López Ibor, MI | 1 |
| Maestú, F | 1 |
| Campo, P | 1 |
| López Ibor, JJ | 1 |
| Ortiz, T | 1 |
| Obermayr, RP | 1 |
| Mayerhofer, L | 1 |
| Knechtelsdorfer, M | 1 |
| Mersich, N | 1 |
| Huber, ER | 1 |
| Geyer, G | 1 |
| Tragl, KH | 1 |
| Zizzari, P | 1 |
| Bassant, MH | 1 |
| Poindessous-Jazat, F | 1 |
| Epelbaum, J | 1 |
| Bluet-Pajot, MT | 1 |
| Hernandez, CM | 1 |
| Gearhart, DA | 1 |
| Parikh, V | 1 |
| Hohnadel, EJ | 2 |
| Davis, LW | 1 |
| Middlemore, ML | 1 |
| Warsi, SP | 1 |
| Waller, JL | 1 |
| Hornung, OP | 1 |
| Regen, F | 1 |
| Danker-Hopfe, H | 1 |
| Schredl, M | 2 |
| Heuser, I | 2 |
| Béracochéa, D | 1 |
| Philippin, JN | 2 |
| Meunier, S | 1 |
| Morain, P | 2 |
| Bernard, K | 1 |
| Webster, SJ | 1 |
| Martin, D | 1 |
| Bouchard, KA | 1 |
| Warner, SE | 1 |
| Marighetto, A | 1 |
| Valerio, S | 1 |
| Desmedt, A | 1 |
| Trocmé-Thibierge, C | 1 |
| Ohnishi, A | 1 |
| Mihara, M | 1 |
| Kamakura, H | 1 |
| Tomono, Y | 1 |
| Hasegawa, J | 1 |
| Yamazaki, K | 1 |
| Morishita, N | 1 |
| Tanaka, T | 1 |
| Henry, RG | 1 |
| Wekstein, DR | 1 |
| Kosasa, T | 1 |
| Kuriya, Y | 1 |
| Matsui, K | 1 |
| Yamanishi, Y | 1 |
| Weber, B | 1 |
| Leins, ML | 1 |
| Devi, G | 1 |
| Silver, J | 1 |
| Yesavage, JA | 1 |
| Mumenthaler, MS | 1 |
| Taylor, JL | 1 |
| Friedman, L | 1 |
| O'Hara, R | 1 |
| Sheikh, J | 1 |
| Tinklenberg, J | 1 |
| Whitehouse, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder[NCT04318639] | Phase 2/Phase 3 | 15 participants (Actual) | Interventional | 2018-08-17 | Completed | ||
| Maintenance Therapies in Late-Life Depression: MTLD III[NCT00177671] | Phase 4 | 220 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment[NCT01876823] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease[NCT02521558] | 30 participants (Actual) | Interventional | 2015-09-30 | Terminated (stopped due to Enrollment was halted early because of low adherence to the intervention.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Recurrence of major depressive episodes as determined by SCID/DSM IV: two weeks of low mood and/or anhedonia, together with at least five of the following symptoms: suicidal ideation, low energy, sleep disturbance, appetite disturbance, psychic anxiety or somatic anxiety. In addition, a diagnosis of major depression requires evidence of distress or impairment. (NCT00177671)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Donepezil | 19 |
| Placebo | 11 |
Conversion to dementia was ascertained by the University of Pittsburgh Alzheimer Disease Research Center (ADRC), using data on neuropsychological performance and IADL functioning, as well as other relevant clinical data. Diagnoses were made according to National Alzheimer Coordinating Center criteria. (NCT00177671)
Timeframe: 2 year
| Intervention | Percent of Participants (Number) |
|---|---|
| Donepezil | 10 |
| Placebo | 33 |
The PASS (a performance-based assessment of instrumental activities of daily living)generates a composite measure of 13 cognitive IADL items capturing performance on activities such as shopping, bill paying, medication management, and home safety. We report the percentage of subjects at each assessment point adjudged to have independent functioning. This was determined by a clinician rater observing subjects perform each task and rating them according to predetermined criteria on a 4 point scale, ranging from 0 (unable) to 3 (independent). (NCT00177671)
Timeframe: baseline, year 1 and year 2
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Baseline (N=33; N=34) | Year 1 (N=23; N=25) | Year 2 (N=11; N=17) | |
| Donepezil | 54.10 | 62.16 | 36.67 |
| Placebo | 61.82 | 54.35 | 47.22 |
Cognitive performance was assessed with 17 well established and validated individual tests measuring multiple domains. We transformed raw scores for individual tests into Z-scores using the baseline distribution of a non-depressed, cognitively normal, older adult comparison group (N=36)of similar age, education, and medical health recruited concurrently with the depressed participants. These Z-scores were averaged within each neuropsychological area to produce domain scores and then averaged over all 17 tests to calculate a global cognition performance score. (NCT00177671)
Timeframe: Measured at baseline and Years 1 and 2 in maintenance
| Intervention | Z-score (Mean) | ||
|---|---|---|---|
| Baseline (N=67;N=63) | Year 1 (N=45; N=57) | Year 2 N=42; N=49) | |
| Donepezil | -0.47 | -0.23 | -0.31 |
| Placebo | -0.47 | -0.65 | -0.56 |
Change in 24-item Hamilton Rating Scale for Depression (HAMD) scores from baseline to Week 48: HAMD measures depression severity based on a series of 24 items items. The range of HAMD total score is 0-74; 0 indicates no depressive symptoms and a maximum HAMD score is a 74, where the greater the score indicates more significant psychopathology. In this study, moderate to severe depression is considered a HAMD-24 greater than 14. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | scores on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -15.2 |
Change in Selective Reminding Test-Delayed Recall scores from baseline to Week 48: SRT Delay is administered 15 minutes after the immediate recall portion. Patients are asked to remember as many of the words as they can from the 6 trials. Maximum raw score is a 12 for free recall. If a patient is unable to recall a word, they are given a chance to recognize it among three incorrect word choices. Maximum raw score for recognition is 12. The greater the score on the delayed recall portion, the better the patient does on the assessment. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.2 |
Change in Selective Reminding Test-Total Immediate Recall (SRT-IR) scores from baseline to Week 48: Measures word recall (maximum 12 words per trial, across 6 trials). Maximum total recall score across 6 trials is 72; minimum recall is 0 across 6 trials. The higher the raw score, the better the patient did at recalling the target words. The unit of measure is the raw score, or the sum of the number of words recalled across all 6 trials. (NCT01876823)
Timeframe: baseline, 48 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 7.5 |
Change in Trails A scores from baseline to Week 48: Measures attention and executive function. It asks patients to connect numbers from 1-25 in numerical order as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 1.9 |
Change from baseline to Week 48 on Trails B: Measures attention and executive function. It asks patients to connect numbers and letters in numerical to alphabetical order from (1-13 and A-L) as fast as they can. Patients are timed; the longer it takes for the patient to connect the numbers and letters, the worse their score. Unit of measure is in seconds. The amount of errors that the patient makes during trails is also recorded. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | seconds (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | -36.3 |
Change in Wechsler Memory Scale-III scores from baseline to Week 48: The WMS-III Visual Reproduction sub-test was used to measure visual working memory and delayed memory. Patients were shown pictures of four drawings and were asked to reproduce them from memory immediately after seeing them, and 25 minutes after seeing them. The four scores are summed and the greater the total raw score, the better the patient did on the assessment. The maximum raw score for this test is a 41 on both the immediate and delayed portions (the overall range is 0-82 points). The change score is calculated using the total scores of both the immediate and delayed portions. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) |
|---|---|
| Es-citalopram and Memantine Treatment | 9.9 |
The CDR is a numeric rating scale that is used to quantify the severity of one's cognitive function. The scale goes from 0=normal; 0.5=mild cognitive impairment; 1 to 3=mild to moderate/severe dementia. CDR was used a dichotomous outcome measure (no=0; yes=1). (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | participants (Number) |
|---|---|
| Es-citalopram and Memantine Treatment | 1 |
The CGI Cognitive Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses from the entire group were calculated. Mean at final visit and baseline is reported below. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| CGI-Cognitive Change (Baseline) | Clinical Global Impression-Cogntive Change (WK 48) | |
| Es-citalopram and Memantine Treatment | 3.6 | 2.7 |
The CGI Depression Change follows a seven-point likert scale. Compared to the patient's condition at baseline in the study [prior to medication initiation], the patient's condition is rated as: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment. Responses were calculated for the entire group. Mean at final visit has been reported below. Higher mean at baseline indicates a decrease in depression scores. (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Cognitive Global Impression at Baseline | Cognitive Global Impression at Final Visit (WK 48) | |
| Es-citalopram and Memantine Treatment | 4.1 | 2.1 |
"Somatic side effect rating scale which includes 26 common somatic side effects associated with previous medication clinical trials; rated by the study physician. Factors were dichotomized to yes or no responses on this scale, which equated to the symptom being either present or not present. Yes and no responses were given a value of 0 (no) or 1 (yes). Responses from the entire group were calculated and the mean at baseline and the last visit is reported below." (NCT01876823)
Timeframe: Baseline, Week 48
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Treatment Emergent Side Effects (Baseline) | Treatment Emergent Side Effects (WK 48) | |
| Es-citalopram and Memantine Treatment | 6.6 | 3.2 |
6 reviews available for donepezil and Aging
| Article | Year |
|---|---|
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; G | 2013 |
Atypical aging in Down syndrome.
Topics: Adult; Aging; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Dementia; Donepez | 2013 |
The costs of Alzheimer's disease and the value of effective therapies.
Topics: Age Factors; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Ga | 2011 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; | 2002 |
Providing dental care for patients diagnosed with Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Caregivers; Cholinesterase | 1997 |
Approaches to memory loss in neuropsychiatric disorders.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cholinesterase Inhibitors; Dementia; D | 2000 |
7 trials available for donepezil and Aging
| Article | Year |
|---|---|
From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Amino Acid Sequence; Animals; Blood Pressure; CHO | 2021 |
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cholinesterase In | 2011 |
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cholinesterase In | 2011 |
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cholinesterase In | 2011 |
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aging; Antidepressive Agents; Cholinesterase In | 2011 |
Effects of cholinergic drugs and cognitive training on dementia.
Topics: Aged; Aging; Alzheimer Disease; Cholinergic Agents; Cognition; Cognitive Behavioral Therapy; Combine | 2004 |
The age-related down-regulation of the growth hormone/insulin-like growth factor-1 axis in the elderly male is reversed considerably by donepezil, a drug for Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Analysis of Variance; Area Under Curve; Cholinesterase Inhibitors; D | 2005 |
The relationship between REM sleep and memory consolidation in old age and effects of cholinergic medication.
Topics: Aged; Aged, 80 and over; Aging; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; H | 2007 |
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Alzheimer Disease; Cholinesterase Inhibitors; Chromatograp | 1993 |
Donepezil and flight simulator performance: effects on retention of complex skills.
Topics: Adult; Aged; Aging; Aviation; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Humans; Ind | 2002 |
44 other studies available for donepezil and Aging
| Article | Year |
|---|---|
A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment.
Topics: Aging; Animals; Blood-Brain Barrier; Brain; Cells, Cultured; Cognition Disorders; Donepezil; Drug Ev | 2020 |
Concurrent administration of thyroxine and donepezil induces plastic changes in the prefrontal cortex of adult hypothyroid rats.
Topics: Aging; Animals; Donepezil; Hypothyroidism; Indans; Male; Neuronal Plasticity; Piperidines; Prefronta | 2017 |
Effects of acute administration of donepezil or memantine on sleep-deprivation-induced spatial memory deficit in young and aged non-human primate grey mouse lemurs (Microcebus murinus).
Topics: Aging; Alzheimer Disease; Animals; Cheirogaleidae; Disease Models, Animal; Donepezil; Indans; Male; | 2017 |
Donepezil Reverses Dendritic Spine Morphology Adaptations and Fmr1 Epigenetic Modifications in Hippocampus of Adult Rats After Adolescent Alcohol Exposure.
Topics: Acetylation; Aging; Animals; Dendritic Spines; Donepezil; Epigenesis, Genetic; Ethanol; Fragile X Me | 2018 |
The location discrimination reversal task in mice is sensitive to deficits in performance caused by aging, pharmacological and other challenges.
Topics: Aging; Animals; Conditioning, Operant; Discrimination, Psychological; Dizocilpine Maleate; Donepezil | 2018 |
Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Brain; Calcineurin; Calcineurin Inhibitors; | 2018 |
Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice.
Topics: Aging; Animals; Donepezil; Drug Synergism; Flumazenil; GABA-A Receptor Agonists; Indans; Male; Maze | 2014 |
Age-Related Decline in Brain and Hepatic Clearance of Amyloid-Beta is Rectified by the Cholinesterase Inhibitors Donepezil and Rivastigmine in Rats.
Topics: Aging; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Brain; Cholinesterase Inhibitors; Donepe | 2015 |
The selective positive allosteric M1 muscarinic receptor modulator PQCA attenuates learning and memory deficits in the Tg2576 Alzheimer's disease mouse model.
Topics: Aging; Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; Disease Models, An | 2015 |
Minocycline enhances hippocampal memory, neuroplasticity and synapse-associated proteins in aged C57 BL/6 mice.
Topics: Aging; Animals; Avoidance Learning; Brain-Derived Neurotrophic Factor; Cytoskeletal Proteins; Dendri | 2015 |
Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil.
Topics: Aging; Alzheimer Disease; Animals; beta-Galactosidase; Cholinesterase Inhibitors; Cognition; Disease | 2015 |
Effects of Ginkgo biloba Extract EGb 761, Donepezil and their Combination on Central Cholinergic Function in Aged Rats.
Topics: Acetylcholine; Aging; Animals; Brain; Choline; Choline O-Acetyltransferase; Cholinesterase Inhibitor | 2015 |
Discrimination performance in aging is vulnerable to interference and dissociable from spatial memory.
Topics: Acetylcholine; Aging; Animals; Cholinesterase Inhibitors; Discrimination, Psychological; Donepezil; | 2016 |
Ferulic acid ameliorates memory impairment in d-galactose-induced aging mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Brain; Caspase 3; Coumaric Acids; Disease Models | 2016 |
Donepezil: It is time to replace physostigmine in Anesthesiology.
Topics: Aging; Anesthesia, General; Anesthesiology; Anesthetics; Brain; Cholinergic Neurons; Cholinesterase | 2016 |
Inhibitor of Phosphodiestearse-4 improves memory deficits, oxidative stress, neuroinflammation and neuropathological alterations in mouse models of dementia of Alzheimer's Type.
Topics: Acetylcholinesterase; Aging; Alzheimer Disease; Animals; Antioxidants; Brain; Cholinesterase Inhibit | 2017 |
Tropisetron sensitizes α7 containing nicotinic receptors to low levels of acetylcholine in vitro and improves memory-related task performance in young and aged animals.
Topics: Acetylcholine; Aging; alpha7 Nicotinic Acetylcholine Receptor; Animals; Donepezil; Dose-Response Rel | 2017 |
Early postnatal maternal deprivation in rats induces memory deficits in adult life that can be reversed by donepezil and galantamine.
Topics: Acetylcholine; Acetylcholinesterase; Aging; Animals; Animals, Newborn; Brain; Disease Models, Animal | 2009 |
Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis.
Topics: Aging; Animals; Brain; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Cognition; Conditioni | 2009 |
Cholinergic activation of hippocampal neural stem cells in aged dentate gyrus.
Topics: Acetylcholine; Aging; Animals; Cell Proliferation; Cholinesterase Inhibitors; Dentate Gyrus; Donepez | 2011 |
Enhanced dendritic spine number of neurons of the prefrontal cortex, hippocampus, and nucleus accumbens in old rats after chronic donepezil administration.
Topics: Aging; Animals; Brain; Dendritic Spines; Donepezil; Hippocampus; Indans; Male; Neurons; Nootropic Ag | 2010 |
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; | 2010 |
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Topics: Aging; Animals; Biological Availability; Brain; Cholinesterase Inhibitors; Cholinesterases; Donepezi | 2011 |
Protective potential of Bacopa monniera (Brahmi) extract on aluminum induced cerebellar toxicity and associated neuromuscular status in aged rats.
Topics: Aging; Aluminum; Animals; Bacopa; Cerebellum; Donepezil; Indans; Male; Motor Activity; Neuromuscular | 2011 |
Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs.
Topics: Aging; Analysis of Variance; Animals; Behavior, Animal; Cholinergic Antagonists; Cholinesterase Inhi | 2011 |
Working memory in the aged Ts65Dn mouse, a model for Down syndrome.
Topics: Aging; Animals; Antidepressive Agents; Central Nervous System Stimulants; Cognition; Conditioning, O | 2012 |
Effects of Gossypium herbaceam extract administration on the learning and memory function in the naturally aged rats: neuronal niche improvement.
Topics: Aging; Analysis of Variance; Animals; Avoidance Learning; Behavior, Animal; Brain-Derived Neurotroph | 2012 |
Combined administration of cerebrolysin and donepezil induces plastic changes in prefrontal cortex in aged mice.
Topics: Aging; Amino Acids; Animals; Dendritic Spines; Donepezil; Drug Synergism; Indans; Male; Mice; Motor | 2012 |
Diverse age-related effects of Bacopa monnieri and donepezil in vitro on cytokine production, antioxidant enzyme activities, and intracellular targets in splenocytes of F344 male rats.
Topics: Aging; Animals; Bacopa; Cell Proliferation; Cells, Cultured; Cytokines; Donepezil; Enzyme Activation | 2013 |
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
Topics: Acetylcholine; Aging; Animals; Body Weight; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhib | 2002 |
Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats.
Topics: Aging; Animals; Avoidance Learning; Basal Nucleus of Meynert; Benzamides; Donepezil; Dose-Response R | 2002 |
FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats.
Topics: Aging; Animals; Benzamides; Cell Count; Donepezil; Hippocampus; Indans; Male; Nootropic Agents; Pipe | 2002 |
Sex dimorphisms in the cognitive-enhancing action of the Alzheimer's drug donepezil in aged Rhesus monkeys.
Topics: Aging; Animals; Cholinesterase Inhibitors; Cognition; Donepezil; Dose-Response Relationship, Drug; F | 2003 |
The impact of drugs against dementia on cognition in aging and mild cognitive impairment.
Topics: Adult; Aged; Aged, 80 and over; Aging; Cognition; Cognition Disorders; Dementia; Donepezil; Female; | 2003 |
Technical issues in the determination of cerebrovascular reserve in elderly subjects using 15O-water PET imaging.
Topics: Acetazolamide; Aged; Aged, 80 and over; Aging; Alzheimer Disease; Attention; Blood Flow Velocity; Br | 2004 |
Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: Functional imaging of the conscious monkey brain using animal PET in combination with microdialysis.
Topics: Aging; Animals; Behavior, Animal; Carbon Radioisotopes; Cholinergic Fibers; Cholinesterase Inhibitor | 2004 |
Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.
Topics: Age Factors; Aging; Animals; Cognition; Cognition Disorders; Donepezil; Dose-Response Relationship, | 2004 |
Donepezil restores GH secretion in old rats without affecting the sleep/wake cycle.
Topics: Acetylcholinesterase; Aging; Animals; Arousal; Cholinesterase Inhibitors; Donepezil; Electroencephal | 2006 |
Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats.
Topics: Acetylcholinesterase; Aging; Animals; Autoradiography; Brain; Choline O-Acetyltransferase; Cholinest | 2006 |
Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil.
Topics: Aging; Animals; Benzothiadiazines; Discrimination Learning; Donepezil; Indans; Male; Memory; Mice; M | 2007 |
The scopolamine-reversal paradigm in rats and monkeys: the importance of computer-assisted operant-conditioning memory tasks for screening drug candidates.
Topics: Aging; Animals; Cholinesterase Inhibitors; Computers; Conditioning, Operant; Discrimination Learning | 2008 |
Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice.
Topics: Aging; alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Animals; Choice Behavior; Choline | 2008 |
Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats.
Topics: Aging; Animals; Brain; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Erythrocytes; Indans; | 1999 |
Donepezil-induced REM sleep augmentation enhances memory performance in elderly, healthy persons.
Topics: Aged; Aging; Animals; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Learning; Male; | 2001 |